National Biospecimen Network - National Cancer Institute - Intranet
HomeNBN BlueprintAbout the PilotIntranetCalendarPublicationsContacts
You are here: Home > NBN Blueprint > Appendix G
 
 
Table of Contents

 

 

PDF Document Full NBN Blueprint Report
(PDF Document - 7,237 kb)
 
Public Comments

   

NBN Blueprint
Appendix G

Examples of Potential Needs and Uses for Biospecimens by Constituency

User Type Needs Uses
Academic Researchers 20-100 samples or more per experiment

< 100 mg to 100-200mg

Standard clinical quality

RNA grade

Protein grade
Biology (genetic basis of human disease)

Aberrations of signal transduction

Genomic analysis, i.e., mutation screening, loss-ofheterzygosity studies, etc.
Pharmaceutical Companies 20-100 samples per experiment

Multiple experiments (~ 1,000 samples per year)

< 100 mg to 100-200 mg

Standard clinical quality

RNA grade

Protein grade
Drug and diagnostics development

Target credentialing and validation
Biotechnology Companies 20-100 samples per experiment

Multiple experiments (~ 1,000 samples per year)

< 100 mg to 100-200 mg

Standard clinical quality

RNA grade

Protein grade
Biomarker discovery and validation

Target identification

 

Return to Table of Contents

Next Appendix: Appendix H: Guidance on Informed Consent for Tissue Repositories

Top of Page

 

 
Home  |  NBN Blueprint  |  About the Pilot  |  Intranet  |  Calendar  |  Publications  |  Contacts
U.S. Department of Health and Human Services - National Institutes of Health - National Cancer Institute
U.S. Department of Health and Human Services
National Institutes of Health
National Cancer Institute